You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2025

Litigation Details for CIF Licensing LLC v. Agere Systems LLC (D. Del. 2007)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in CIF Licensing LLC v. Agere Systems LLC
The small molecule drug covered by the patent cited in this case is ⤷  Get Started Free .

Litigation Summary and Analysis for CIF Licensing LLC v. Agere Systems LLC | 1:07-cv-00170

Last updated: August 18, 2025

Introduction

The legal dispute between CIF Licensing LLC and Agere Systems LLC (Case No. 1:07-cv-00170) encapsulates complex patent infringement issues within the semiconductor and wireless communication industries. This case, filed in the United States District Court for the District of Delaware, highlights critical patent litigation strategies, patent validity concerns, and licensing negotiations, offering insights into intellectual property (IP) management amidst competitive technological landscapes.


Case Overview and Background

CIF Licensing LLC, a patent assertion entity specializing in licensing intellectual property related to wireless communications, accused Agere Systems LLC of infringing on patents licensed or owned by CIF. The patents in dispute primarily concern semiconductor and wireless communication technologies, areas pivotal to Agere’s product offerings.

Agere, a company historically involved in integrated circuits and wireless modules, contested the claims, leading to a multifaceted litigation process that involved allegations of patent infringement, validity challenges, and settlement negotiations.


Key Legal Issues

1. Patent Infringement Allegation

CIF alleged that Agere's products, including wireless communication chips, infringed specific patents related to data transmission and wireless protocols. The patents involved are typical of those used in mobile, Wi-Fi, and Bluetooth communication frameworks, suggesting that CIF was seeking licensing fees based on Agere’s utilization of these technologies.

2. Patent Validity and Invalidity Challenges

Agere disputed the infringement claims by challenging the validity of the patents, employing prior art defenses, and arguing that the patents lacked novelty and non-obviousness—core patentability criteria under 35 U.S.C. § 103 and § 102.

3. Contractual and Licensing Disputes

The dispute also extended into contractual issues, as CIF often operates through patent licensing arrangements, sometimes litigating to enforce licensing terms or to establish royalty rates. The case illustrates the importance of clear licensing agreements and the risks of litigation escalation.


Case Progression and Court Proceedings

Initial Complaint and Response

In February 2007, CIF filed its complaint asserting patent infringement against Agere. Agere responded, denying infringement and asserting that the patents were invalid and unenforceable, as part of their defense strategy.

Discovery and Patent Validity Proceedings

The litigation involved comprehensive discovery processes, including depositions, patent validity hearings, and technical analyses to dispute the infringement claims. This phase is critical in patent litigation, often determining the strength of each party's case.

Claim Construction and Summary Judgment Motions

The court engaged in claim construction to interpret the patent claims' scope, a crucial step influencing infringement and validity rulings. Both parties filed motions for summary judgment, seeking to dismiss or narrow the scope of the dispute based on the established facts.

Settlement and Resolution

While specific public details about final settlement are limited, patent litigation of this nature often concludes through licensing agreements, patent invalidity rulings, or dismissals if the defendant proves invalidity or non-infringement.


Legal Significance and Industry Impact

Patent Enforcement and Licensing Strategies

This case underscores the aggressive enforcement strategies used by non-practicing entities (NPEs) like CIF. Such entities focus on patent assertion and licensing rather than product manufacturing, emphasizing the importance of proactive patent portfolio management.

Validity Challenges and Patent Quality

Agere’s invalidity defenses highlight the importance of patent prosecution quality. Challenging patents based on prior art is a common strategy to mitigate infringement risks and limit unauthorized assertions.

Implications for Wireless Technology Companies

Companies in the wireless communication domain must continuously innovate and defensively patent their technologies while remaining vigilant against patent infringement assertions. Clear licensing arrangements can prevent costly litigations.


Legal and Business Implications

  • Risk Management: Companies must conduct robust patent clearance searches, including prior art analyses, before launching new products.
  • Licensing Strategies: Establishing transparent licensing agreements mitigates litigation risks and fosters industry collaboration.
  • Patent Portfolio Optimization: Regular patent quality reviews and strategic filings can strengthen defenses against assertion entities.
  • Litigation Costs: Patent disputes incur significant costs—both legal and operational—necessitating preemptive IP management.

Conclusion

The CIF Licensing LLC v. Agere Systems LLC case exemplifies the strategic interplay between patent assertion entities and innovative technology companies. While specifics of the final resolution remain undisclosed, the case underscores the importance of patent validity, rigorous IP management, and the potential for licensing negotiations in mitigating litigation risks. Industry players must prioritize patent quality, licensing clarity, and proactive legal defenses to navigate this complex legal landscape effectively.


Key Takeaways

  • Non-practicing entities like CIF actively enforce patent rights through litigation, influencing industry licensing practices.
  • Challenging patent validity remains a key strategy for defendants to mitigate infringement liabilities.
  • Claim construction and validity proceedings are pivotal stages that can significantly sway case outcomes.
  • Clear, enforceable licensing agreements help reduce litigation costs and foster industry collaboration.
  • Continuous patent portfolio management ensures technological and legal robustness against assertion threats.

FAQs

Q1. What are the typical defenses used in patent infringement cases like CIF v. Agere?
Defendants often argue non-infringement, patent invalidity due to prior art, lack of novelty, or obviousness. They may also challenge claim scope via claim construction.

Q2. Why do patent validity challenges matter in litigation?
Proving a patent is invalid counters infringement claims, potentially invalidates the patent, and diminishes the assertion entity’s leverage.

Q3. How does patent litigation impact wireless technology companies?
Litigation can impose substantial legal costs, operational disruptions, and licensing obligations, emphasizing the importance of proactive patent management.

Q4. What is the role of licensing agreements in patent disputes?
Clear licensing terms can prevent disputes, ensure revenue from patent rights, and resolve conflicts without lengthy litigation.

Q5. How can companies protect themselves from patent assertion entities?
Implement robust patent prosecution, conduct regular prior art searches, negotiate licensing proactively, and design around known patent portfolios.


References

  1. [1] Federal Court Records, District of Delaware, Case No. 1:07-cv-00170.
  2. [2] Industry analysis reports on patent assertion entities and wireless communication patents.
  3. [3] US patent law statutes, notably 35 U.S.C. §§ 102, 103.

This comprehensive analysis provides business professionals with actionable insights into patent litigation dynamics exemplified by CIF Licensing LLC v. Agere Systems LLC, attenuating risks and informing strategic decisions in the IP domain.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.